<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.2.269">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">

<meta name="author" content="David Miller">
<meta name="dcterms.date" content="2023-01-13">

<title>Cutaneous Oncology Interest Group - Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1.6em;
  vertical-align: middle;
}
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>


<script src="../../site_libs/quarto-nav/quarto-nav.js"></script>
<script src="../../site_libs/quarto-nav/headroom.min.js"></script>
<script src="../../site_libs/clipboard/clipboard.min.js"></script>
<script src="../../site_libs/quarto-search/autocomplete.umd.js"></script>
<script src="../../site_libs/quarto-search/fuse.min.js"></script>
<script src="../../site_libs/quarto-search/quarto-search.js"></script>
<meta name="quarto:offset" content="../../">
<script src="../../site_libs/quarto-html/quarto.js"></script>
<script src="../../site_libs/quarto-html/popper.min.js"></script>
<script src="../../site_libs/quarto-html/tippy.umd.min.js"></script>
<script src="../../site_libs/quarto-html/anchor.min.js"></script>
<link href="../../site_libs/quarto-html/tippy.css" rel="stylesheet">
<link href="../../site_libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" class="quarto-color-scheme" id="quarto-text-highlighting-styles">
<link href="../../site_libs/quarto-html/quarto-syntax-highlighting-dark.css" rel="prefetch" class="quarto-color-scheme quarto-color-alternate" id="quarto-text-highlighting-styles">
<script src="../../site_libs/bootstrap/bootstrap.min.js"></script>
<link href="../../site_libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="../../site_libs/bootstrap/bootstrap.min.css" rel="stylesheet" class="quarto-color-scheme" id="quarto-bootstrap" data-mode="light">
<link href="../../site_libs/bootstrap/bootstrap-dark.min.css" rel="prefetch" class="quarto-color-scheme quarto-color-alternate" id="quarto-bootstrap" data-mode="dark">
<script id="quarto-search-options" type="application/json">{
  "location": "navbar",
  "copy-button": false,
  "collapse-after": 3,
  "panel-placement": "end",
  "type": "overlay",
  "limit": 20,
  "language": {
    "search-no-results-text": "No results",
    "search-matching-documents-text": "matching documents",
    "search-copy-link-title": "Copy link to search",
    "search-hide-matches-text": "Hide additional matches",
    "search-more-match-text": "more match in this document",
    "search-more-matches-text": "more matches in this document",
    "search-clear-button-title": "Clear",
    "search-detached-cancel-button-title": "Cancel",
    "search-submit-button-title": "Submit"
  }
}</script>
<script src="../../site_libs/htmlwidgets-1.6.0/htmlwidgets.js"></script>
<script src="../../site_libs/plotly-binding-4.10.1.9000/plotly.js"></script>
<script src="../../site_libs/typedarray-0.1/typedarray.min.js"></script>
<script src="../../site_libs/jquery-3.5.1/jquery.min.js"></script>
<link href="../../site_libs/crosstalk-1.2.0/css/crosstalk.min.css" rel="stylesheet">
<script src="../../site_libs/crosstalk-1.2.0/js/crosstalk.min.js"></script>
<link href="../../site_libs/plotly-htmlwidgets-css-2.11.1/plotly-htmlwidgets.css" rel="stylesheet">
<script src="../../site_libs/plotly-main-2.11.1/plotly-latest.min.js"></script>


<link rel="stylesheet" href="../../styles.css">
</head>

<body class="nav-fixed">

<div id="quarto-search-results"></div>
  <header id="quarto-header" class="headroom fixed-top">
    <nav class="navbar navbar-expand-lg navbar-dark ">
      <div class="navbar-container container-fluid">
      <div class="navbar-brand-container">
    <a class="navbar-brand" href="../../index.html">
    <span class="navbar-title">Cutaneous Oncology Interest Group</span>
    </a>
  </div>
          <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbarCollapse" aria-controls="navbarCollapse" aria-expanded="false" aria-label="Toggle navigation" onclick="if (window.quartoToggleHeadroom) { window.quartoToggleHeadroom(); }">
  <span class="navbar-toggler-icon"></span>
</button>
          <div class="collapse navbar-collapse" id="navbarCollapse">
            <ul class="navbar-nav navbar-nav-scroll ms-auto">
  <li class="nav-item">
    <a class="nav-link" href="../../jc.html">
 <span class="menu-text">Journal Club</span></a>
  </li>  
  <li class="nav-item">
    <a class="nav-link" href="../../perspectives.html">
 <span class="menu-text">Perspectives on the Science</span></a>
  </li>  
</ul>
              <div class="quarto-toggle-container">
                  <a href="" class="quarto-color-scheme-toggle nav-link" onclick="window.quartoToggleColorScheme(); return false;" title="Toggle dark mode"><i class="bi"></i></a>
                  <a href="" class="quarto-reader-toggle nav-link" onclick="window.quartoToggleReader(); return false;" title="Toggle reader mode">
  <div class="quarto-reader-toggle-btn">
  <i class="bi"></i>
  </div>
</a>
              </div>
              <div id="quarto-search" class="" title="Search"></div>
          </div> <!-- /navcollapse -->
      </div> <!-- /container-fluid -->
    </nav>
</header>
<!-- content -->
<div id="quarto-content" class="quarto-container page-columns page-rows-contents page-layout-article page-navbar">
<!-- sidebar -->
<!-- margin-sidebar -->
    <div id="quarto-margin-sidebar" class="sidebar margin-sidebar">
        <nav id="TOC" role="doc-toc" class="toc-active">
    <h2 id="toc-title">On this page</h2>
   
  <ul>
  <li><a href="#featured-article" id="toc-featured-article" class="nav-link active" data-scroll-target="#featured-article">Featured Article</a></li>
  <li><a href="#introduction" id="toc-introduction" class="nav-link" data-scroll-target="#introduction">Introduction</a></li>
  <li><a href="#background-for-the-study" id="toc-background-for-the-study" class="nav-link" data-scroll-target="#background-for-the-study">Background for the Study</a></li>
  <li><a href="#study-design" id="toc-study-design" class="nav-link" data-scroll-target="#study-design">Study Design</a></li>
  <li><a href="#main-findings" id="toc-main-findings" class="nav-link" data-scroll-target="#main-findings">Main Findings</a></li>
  <li><a href="#discussion-points" id="toc-discussion-points" class="nav-link" data-scroll-target="#discussion-points">Discussion Points</a>
  <ul class="collapse">
  <li><a href="#materials-and-methods" id="toc-materials-and-methods" class="nav-link" data-scroll-target="#materials-and-methods">Materials and Methods</a></li>
  </ul></li>
  <li><a href="#author-affiliations" id="toc-author-affiliations" class="nav-link" data-scroll-target="#author-affiliations">Author Affiliations</a>
  <ul class="collapse">
  <li><a href="#disclosures" id="toc-disclosures" class="nav-link" data-scroll-target="#disclosures">Disclosures</a></li>
  </ul></li>
  </ul>
</nav>
    </div>
<!-- main -->
<main class="content" id="quarto-document-content">

<header id="title-block-header" class="quarto-title-block default">
<div class="quarto-title">
<h1 class="title">Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma</h1>
</div>



<div class="quarto-title-meta">

    <div>
    <div class="quarto-title-meta-heading">Author</div>
    <div class="quarto-title-meta-contents">
             <p>David Miller </p>
          </div>
  </div>
    
    <div>
    <div class="quarto-title-meta-heading">Published</div>
    <div class="quarto-title-meta-contents">
      <p class="date">January 13, 2023</p>
    </div>
  </div>
  
    
  </div>
  

</header>

<section id="featured-article" class="level1">
<h1>Featured Article</h1>
<hr>
<p><strong>Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma</strong>. Rohaan et al.&nbsp;NEJM. 2022 Dec 8;387(23):2113-2125.</p>
<hr>
</section>
<section id="introduction" class="level1">
<h1>Introduction</h1>
<p>On January 9<sup>th</sup>, 2023, the multi-institutional Cutaneous Oncology Interest Group Journal Club reviewed the recently published NEJM article “Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.”<span class="citation" data-cites="Rohaan2022"><sup><a href="#ref-Rohaan2022" role="doc-biblioref">1</a></sup></span> Participants included clinicians and investigators from Massachusetts General Hospital, Mass Eye and Ear, Brigham and Women’s Hospital, the National Institutes of Health, George Washington Medical Center, the University of Pittsburgh Medical Center and the Northwestern Feinberg School of Medicine. Importantly, the comments in this article represent the views of the authors of this Perspectives on the Science piece after the Journal Club. It does not represent views of any other members of the Interest Group or the affiliated institutions. In this article we provide a summary of the discussion regarding this important contribution to the literature.</p>
</section>
<section id="background-for-the-study" class="level1">
<h1>Background for the Study</h1>
<p>Treatment options for melanoma have advanced greatly in the last several years and continue to evolve (<strong>Figure 1</strong>). Landmark studies such as KEYNOTE-001/006 and CheckMate-066 have led to single-agent immunotherapy with anti-PD-1 immune checkpoint inhibitors becoming a first-line treatment options for advanced, unresectable melanoma (<strong>Figure 2</strong>).<span class="citation" data-cites="Hamid2019 Robert2015 Robert2019 Schachter2017 Petrella2017"><sup><a href="#ref-Hamid2019" role="doc-biblioref">2</a>–<a href="#ref-Petrella2017" role="doc-biblioref">6</a></sup></span> Subsequent studies such as CheckMate-067 and RELATIVITY-047 have positioned dual immune checkpoint blockade (ICB) with aPD-1/aCTLA-4 and aPD-1/aLAG-3 monoclonal antibodies as additional options in the front-line setting for appropriate patients.<span class="citation" data-cites="wolchok2017 tawbi2022 long2022"><sup><a href="#ref-wolchok2017" role="doc-biblioref">7</a>–<a href="#ref-long2022" role="doc-biblioref">9</a></sup></span> In addition combined BRAF and MEK inhibition may be efficacious for melanomas with BRAF mutations<span class="citation" data-cites="robert2019a dummer2018"><sup><a href="#ref-robert2019a" role="doc-biblioref">10</a>,<a href="#ref-dummer2018" role="doc-biblioref">11</a></sup></span></p>
<div class="cell">

</div>
<div class="callout-note callout callout-style-simple no-icon callout-captioned">
<div class="callout-header d-flex align-content-center" data-bs-toggle="collapse" data-bs-target=".callout-1-contents" aria-controls="callout-1" aria-expanded="false" aria-label="Toggle callout">
<div class="callout-icon-container">
<i class="callout-icon no-icon"></i>
</div>
<div class="callout-caption-container flex-fill">
Figure 1. Evolving treatment landscape in melanoma.
</div>
<div class="callout-btn-toggle d-inline-block border-0 py-1 ps-1 pe-0 float-end"><i class="callout-toggle"></i></div>
</div>
<div id="callout-1" class="callout-1-contents callout-collapse collapse">
<div class="callout-body-container callout-body">
<div class="cell">
<div class="cell-output-display">

<div class="plotly html-widget html-fill-item-overflow-hidden html-fill-item" id="htmlwidget-547068a6159d3105884d" style="width:100%;height:928px;"></div>
<script type="application/json" data-for="htmlwidget-547068a6159d3105884d">{"x":{"data":[{"x":[-2847.25,21160.25],"y":[50,50],"text":"","type":"scatter","mode":"lines","line":{"width":1.88976377952756,"color":"rgba(0,0,0,1)","dash":"solid"},"hoveron":"points","showlegend":false,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null},{"x":[-2847.25,21160.25],"y":[100,100],"text":"","type":"scatter","mode":"lines","line":{"width":1.88976377952756,"color":"rgba(255,255,255,1)","dash":"solid"},"hoveron":"points","showlegend":false,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null},{"x":[-2847.25,21160.25],"y":[0,0],"text":"","type":"scatter","mode":"lines","line":{"width":1.88976377952756,"color":"rgba(255,255,255,1)","dash":"solid"},"hoveron":"points","showlegend":false,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null},{"x":[-756,-756,null,1972,1972,null,9469,9469,null,10235,10235,null,15058,15058,null,15062,15062,null,15203,15203,null,15854,15854,null,15854,15854,null,16078,16078,null,16079,16079,null,16317,16317,null,16426,16426,null,16708,16708,null,16735,16735,null,16736,16736,null,16749,16749,null,16759,16759,null,16759,16759,null,16762,16762,null,16787,16787,null,16787,16787,null,16823,16823,null,16823,16823,null,17057,17057,null,17057,17057,null,17303,17303,null,17368,17368,null,17520,17520,null,17540,17540,null,17557,17557,null,17595,17595,null,17595,17595,null,17595,17595,null,17651,17651,null,17651,17651,null,17709,17709,null,17709,17709,null,17942,17942,null,17962,17962,null,17962,17962,null,18175,18175,null,18175,18175,null,18380,18380,null,18473,18473,null,18964,18964,null,19017,19017,null,19069,19069],"y":[48,50,null,52,50,null,46,50,null,54,50,null,44,50,null,56,50,null,42,50,null,58,50,null,40,50,null,60,50,null,38,50,null,62,50,null,36,50,null,64,50,null,34,50,null,66,50,null,32,50,null,68,50,null,30,50,null,70,50,null,28,50,null,72,50,null,26,50,null,74,50,null,24,50,null,76,50,null,22,50,null,78,50,null,20,50,null,80,50,null,18,50,null,82,50,null,16,50,null,84,50,null,14,50,null,86,50,null,12,50,null,88,50,null,10,50,null,90,50,null,8,50,null,92,50,null,6,50,null,94,50,null,4,50,null,96,50,null,2,50,null,98,50],"text":"","type":"scatter","mode":"lines","line":{"width":1.88976377952756,"color":"rgba(0,0,0,1)","dash":"solid"},"hoveron":"points","showlegend":false,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null},{"x":[1972],"y":[52.5],"text":"Dacarbazine","hovertext":"<b>Drug:<\/b> Dacarbazine<br><b>Date of Approval:<\/b> 1975-05-27<br><b>Indication:<\/b> Metastatic Malignant Melanoma<br><b>Mechanism:<\/b> Alkylating Agent","textfont":{"size":15.1181102362205,"color":"rgba(248,118,109,1)"},"type":"scatter","mode":"text","hoveron":"points","name":"Alkylating Agent","legendgroup":"Alkylating Agent","showlegend":true,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null},{"x":[-756],"y":[47.5],"text":"Hydroxyurea","hovertext":"<b>Drug:<\/b> Hydroxyurea<br><b>Date of Approval:<\/b> 1967-12-07<br><b>Indication:<\/b> Melanoma<br><b>Mechanism:<\/b> Antimetabolite","textfont":{"size":15.1181102362205,"color":"rgba(216,144,0,1)"},"type":"scatter","mode":"text","hoveron":"points","name":"Antimetabolite","legendgroup":"Antimetabolite","showlegend":true,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null},{"x":[19017],"y":[1.5],"text":"Tebentafusp-Tebn","hovertext":"<b>Drug:<\/b> Tebentafusp-Tebn<br><b>Date of Approval:<\/b> 2022-01-25<br><b>Indication:<\/b> HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma<br><b>Mechanism:<\/b> Bispecific Antibody","textfont":{"size":15.1181102362205,"color":"rgba(163,165,0,1)"},"type":"scatter","mode":"text","hoveron":"points","name":"Bispecific Antibody","legendgroup":"Bispecific Antibody","showlegend":true,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null},{"x":[15058,16736,17368],"y":[43.5,66.5,78.5],"text":["Ipilimumab","Ipilimumab","Ipilimumab"],"hovertext":["<b>Drug:<\/b> Ipilimumab<br><b>Date of Approval:<\/b> 2011-03-25<br><b>Indication:<\/b> Unresectable or Metastatic Melanoma<br><b>Mechanism:<\/b> CTLA-4 Ab","<b>Drug:<\/b> Ipilimumab<br><b>Date of Approval:<\/b> 2015-10-28<br><b>Indication:<\/b> Adjuvant Melanoma<br><b>Mechanism:<\/b> CTLA-4 Ab","<b>Drug:<\/b> Ipilimumab<br><b>Date of Approval:<\/b> 2017-07-21<br><b>Indication:<\/b> Unresectable or Metastatic Melanoma - patients 12 years and older<br><b>Mechanism:<\/b> CTLA-4 Ab"],"textfont":{"size":15.1181102362205,"color":"rgba(57,182,0,1)"},"type":"scatter","mode":"text","hoveron":"points","name":"CTLA-4 Ab","legendgroup":"CTLA-4 Ab","showlegend":true,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null},{"x":[9469,10235,15062],"y":[45.5,54.5,56.5],"text":["Interferon Alfa-2b","Aldesleukin","Peginterferon Alfa-2b"],"hovertext":["<b>Drug:<\/b> Interferon Alfa-2b<br><b>Date of Approval:<\/b> 1995-12-05<br><b>Indication:<\/b> Adjuvant Melanoma<br><b>Mechanism:<\/b> Cytokine","<b>Drug:<\/b> Aldesleukin<br><b>Date of Approval:<\/b> 1998-01-09<br><b>Indication:<\/b> Metastatic Melanoma<br><b>Mechanism:<\/b> Cytokine","<b>Drug:<\/b> Peginterferon Alfa-2b<br><b>Date of Approval:<\/b> 2011-03-29<br><b>Indication:<\/b> Adjuvant Melanoma<br><b>Mechanism:<\/b> Cytokine"],"textfont":{"size":15.1181102362205,"color":"rgba(0,191,125,1)"},"type":"scatter","mode":"text","hoveron":"points","name":"Cytokine","legendgroup":"Cytokine","showlegend":true,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null},{"x":[15203,15854,15854,16078,16079,16749,16759,16759,17557,17651,17651,17709,17709,18175,18175],"y":[41.5,58.5,39.5,60.5,37.5,31.5,68.5,29.5,17.5,13.5,86.5,11.5,88.5,92.5,5.5],"text":["Vemurafenib","Trametinib Dimethyl Sulfoxide","Dabrafenib Mesylate","Trametinib Dimethyl Sulfoxide","Dabrafenib Mesylate","Cobimetinib Fumarate","Trametinib Dimethyl Sulfoxide","Dabrafenib Mesylate","Cobimetinib Fumarate","Trametinib Dimethyl Sulfoxide","Dabrafenib Mesylate","Encorafenib","Binimetinib","Trametinib Dimethyl Sulfoxide","Dabrafenib Mesylate"],"hovertext":["<b>Drug:<\/b> Vemurafenib<br><b>Date of Approval:<\/b> 2011-08-17<br><b>Indication:<\/b> Unresectable or Metastatic Melanoma<br><b>Mechanism:<\/b> Kinase Inhibitor","<b>Drug:<\/b> Trametinib Dimethyl Sulfoxide<br><b>Date of Approval:<\/b> 2013-05-29<br><b>Indication:<\/b> Unresectable or Metastatic BRAF-Mutated Melanoma<br><b>Mechanism:<\/b> Kinase Inhibitor","<b>Drug:<\/b> Dabrafenib Mesylate<br><b>Date of Approval:<\/b> 2013-05-29<br><b>Indication:<\/b> Single agent, first-line in advanced BRAF-mutated melanoma<br><b>Mechanism:<\/b> Kinase Inhibitor","<b>Drug:<\/b> Trametinib Dimethyl Sulfoxide<br><b>Date of Approval:<\/b> 2014-01-08<br><b>Indication:<\/b> Unresectable or Metastatic BRAF-Mutated Melanoma<br><b>Mechanism:<\/b> Kinase Inhibitor","<b>Drug:<\/b> Dabrafenib Mesylate<br><b>Date of Approval:<\/b> 2014-01-09<br><b>Indication:<\/b> Accelerated approval for Dab/Tram in advanced BRAF mutant melanoma<br><b>Mechanism:<\/b> Kinase Inhibitor","<b>Drug:<\/b> Cobimetinib Fumarate<br><b>Date of Approval:<\/b> 2015-11-10<br><b>Indication:<\/b> Unresectable or Metastatic Melanoma with a BRAF-Mutated Melanoma In Combination with Vemurafenib<br><b>Mechanism:<\/b> Kinase Inhibitor","<b>Drug:<\/b> Trametinib Dimethyl Sulfoxide<br><b>Date of Approval:<\/b> 2015-11-20<br><b>Indication:<\/b> Unresectable or Metastatic Melanoma with a BRAF-Mutated Melanoma In Combination with Dabrafenib<br><b>Mechanism:<\/b> Kinase Inhibitor","<b>Drug:<\/b> Dabrafenib Mesylate<br><b>Date of Approval:<\/b> 2015-11-20<br><b>Indication:<\/b> Regular approval for Dab/Tram in advanced BRAF mutant melanoma<br><b>Mechanism:<\/b> Kinase Inhibitor","<b>Drug:<\/b> Cobimetinib Fumarate<br><b>Date of Approval:<\/b> 2018-01-26<br><b>Indication:<\/b> Updates label to include OS data<br><b>Mechanism:<\/b> Kinase Inhibitor","<b>Drug:<\/b> Trametinib Dimethyl Sulfoxide<br><b>Date of Approval:<\/b> 2018-04-30<br><b>Indication:<\/b> Adjuvant BRAF Mutant Melanoma In Combination with Dabrafenib<br><b>Mechanism:<\/b> Kinase Inhibitor","<b>Drug:<\/b> Dabrafenib Mesylate<br><b>Date of Approval:<\/b> 2018-04-30<br><b>Indication:<\/b> Adjuvant BRAF Mutant Melanoma In Combination with Trametinib<br><b>Mechanism:<\/b> Kinase Inhibitor","<b>Drug:<\/b> Encorafenib<br><b>Date of Approval:<\/b> 2018-06-27<br><b>Indication:<\/b> Regular Approval for use in combination with binimetinib for advanced BRAF mutant melanoma<br><b>Mechanism:<\/b> Kinase Inhibitor","<b>Drug:<\/b> Binimetinib<br><b>Date of Approval:<\/b> 2018-06-27<br><b>Indication:<\/b> Unresectable or Metastatic BRAF-Mutated Melanoma In Combination with Encorafenib<br><b>Mechanism:<\/b> Kinase Inhibitor","<b>Drug:<\/b> Trametinib Dimethyl Sulfoxide<br><b>Date of Approval:<\/b> 2019-10-06<br><b>Indication:<\/b> Updating results  in subjects with brain metastases<br><b>Mechanism:<\/b> Kinase Inhibitor","<b>Drug:<\/b> Dabrafenib Mesylate<br><b>Date of Approval:<\/b> 2019-10-06<br><b>Indication:<\/b> Updates label in regards to brain mets for melanoma<br><b>Mechanism:<\/b> Kinase Inhibitor"],"textfont":{"size":15.1181102362205,"color":"rgba(0,191,196,1)"},"type":"scatter","mode":"text","hoveron":"points","name":"Kinase Inhibitor","legendgroup":"Kinase Inhibitor","showlegend":true,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null},{"x":[19069],"y":[98.5],"text":"Relatlimab-Rmbw","hovertext":"<b>Drug:<\/b> Relatlimab-Rmbw<br><b>Date of Approval:<\/b> 2022-03-18<br><b>Indication:<\/b> Unresectable or Metastatic Melanoma<br><b>Mechanism:<\/b> LAG-3 Ab","textfont":{"size":15.1181102362205,"color":"rgba(0,176,246,1)"},"type":"scatter","mode":"text","hoveron":"points","name":"LAG-3 Ab","legendgroup":"LAG-3 Ab","showlegend":true,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null},{"x":[16735],"y":[33.5],"text":"Talimogene Laherparepvec","hovertext":"<b>Drug:<\/b> Talimogene Laherparepvec<br><b>Date of Approval:<\/b> 2015-10-27<br><b>Indication:<\/b> Unresectable Cutaneous, Subcutaneous, and Nodal Recurrent Melanoma<br><b>Mechanism:<\/b> Oncolytic Virus","textfont":{"size":15.1181102362205,"color":"rgba(149,144,255,1)"},"type":"scatter","mode":"text","hoveron":"points","name":"Oncolytic Virus","legendgroup":"Oncolytic Virus","showlegend":true,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null},{"x":[16317,16426,16708,16762,16787,16787,16823,16823,17057,17057,17303,17520,17540,17595,17595,17595,17942,17962,17962,18380,18964],"y":[62.5,35.5,64.5,70.5,27.5,72.5,25.5,74.5,23.5,76.5,21.5,19.5,80.5,82.5,15.5,84.5,9.5,90.5,7.5,94.5,96.5],"text":["Pembrolizumab","Nivolumab","Nivolumab","Nivolumab","Pembrolizumab","Pembrolizumab","Nivolumab","Nivolumab","Nivolumab","Nivolumab","Pembrolizumab","Nivolumab","Nivolumab","Nivolumab","Nivolumab","Nivolumab","Pembrolizumab","Nivolumab","Nivolumab","Pembrolizumab","Pembrolizumab"],"hovertext":["<b>Drug:<\/b> Pembrolizumab<br><b>Date of Approval:<\/b> 2014-09-04<br><b>Indication:<\/b> Unresectable or Metastatic Melanoma - Second Line<br><b>Mechanism:<\/b> PD-1 Ab","<b>Drug:<\/b> Nivolumab<br><b>Date of Approval:<\/b> 2014-12-22<br><b>Indication:<\/b> Accelerated Approval for Unresectable or Metastatic Melanoma in the Second-Line Setting<br><b>Mechanism:<\/b> PD-1 Ab","<b>Drug:<\/b> Nivolumab<br><b>Date of Approval:<\/b> 2015-09-30<br><b>Indication:<\/b> Accelerated Approval of OPDIVO with YERVOY in BRAF Wild Type Unresectable or Metastatic Melanoma<br><b>Mechanism:<\/b> PD-1 Ab","<b>Drug:<\/b> Nivolumab<br><b>Date of Approval:<\/b> 2015-11-23<br><b>Indication:<\/b> Regular Approval for Unresectable or Metastatic BRAF-Wild Type Melanoma<br><b>Mechanism:<\/b> PD-1 Ab","<b>Drug:<\/b> Pembrolizumab<br><b>Date of Approval:<\/b> 2015-12-18<br><b>Indication:<\/b> Unresectable or Metastatic Melanoma<br><b>Mechanism:<\/b> PD-1 Ab","<b>Drug:<\/b> Pembrolizumab<br><b>Date of Approval:<\/b> 2015-12-18<br><b>Indication:<\/b> Removing language limiting the indication to disease progression following ipilimumab<br><b>Mechanism:<\/b> PD-1 Ab","<b>Drug:<\/b> Nivolumab<br><b>Date of Approval:<\/b> 2016-01-23<br><b>Indication:<\/b> Accelerated Approved for BRAF Mutant Unresectable or Metastatic Melanoma in the First Line Setting<br><b>Mechanism:<\/b> PD-1 Ab","<b>Drug:<\/b> Nivolumab<br><b>Date of Approval:<\/b> 2016-01-23<br><b>Indication:<\/b> Accelerated approval of Ipi/Nivo Expansion for BRAF mutant as well as BRAF WT<br><b>Mechanism:<\/b> PD-1 Ab","<b>Drug:<\/b> Nivolumab<br><b>Date of Approval:<\/b> 2016-09-13<br><b>Indication:<\/b> Flat Dosing for Melanoma, NSCLC and RCC<br><b>Mechanism:<\/b> PD-1 Ab","<b>Drug:<\/b> Nivolumab<br><b>Date of Approval:<\/b> 2016-09-13<br><b>Indication:<\/b> Flat Dosing for Melanoma, NSCLC and RCC<br><b>Mechanism:<\/b> PD-1 Ab","<b>Drug:<\/b> Pembrolizumab<br><b>Date of Approval:<\/b> 2017-05-17<br><b>Indication:<\/b> Flat Dosing of 200 mg q3 weeks in melanoma<br><b>Mechanism:<\/b> PD-1 Ab","<b>Drug:<\/b> Nivolumab<br><b>Date of Approval:<\/b> 2017-12-20<br><b>Indication:<\/b> Regular Approval for Adjuvant Melanoma<br><b>Mechanism:<\/b> PD-1 Ab","<b>Drug:<\/b> Nivolumab<br><b>Date of Approval:<\/b> 2018-01-09<br><b>Indication:<\/b> Updates infusion from 60 to 30 minutes<br><b>Mechanism:<\/b> PD-1 Ab","<b>Drug:<\/b> Nivolumab<br><b>Date of Approval:<\/b> 2018-03-05<br><b>Indication:<\/b> Every 4 Week Dosing for Advanced Melanoma<br><b>Mechanism:<\/b> PD-1 Ab","<b>Drug:<\/b> Nivolumab<br><b>Date of Approval:<\/b> 2018-03-05<br><b>Indication:<\/b> Every 4 week dosing in Adjuvant Melanoma<br><b>Mechanism:<\/b> PD-1 Ab","<b>Drug:<\/b> Nivolumab<br><b>Date of Approval:<\/b> 2018-03-05<br><b>Indication:<\/b> Updates infusion from 60 to 30 minutes in adjuvant Melanoma<br><b>Mechanism:<\/b> PD-1 Ab","<b>Drug:<\/b> Pembrolizumab<br><b>Date of Approval:<\/b> 2019-02-15<br><b>Indication:<\/b> Adjuvant Melanoma<br><b>Mechanism:<\/b> PD-1 Ab","<b>Drug:<\/b> Nivolumab<br><b>Date of Approval:<\/b> 2019-03-07<br><b>Indication:<\/b> Conversion to Regular Approval for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma<br><b>Mechanism:<\/b> PD-1 Ab","<b>Drug:<\/b> Nivolumab<br><b>Date of Approval:<\/b> 2019-03-07<br><b>Indication:<\/b> Conversion to Regular Approval of OPDIVO, in combination with ipilimumab, for the treatment of patients with unresectable or metastatic melanoma<br><b>Mechanism:<\/b> PD-1 Ab","<b>Drug:<\/b> Pembrolizumab<br><b>Date of Approval:<\/b> 2020-04-28<br><b>Indication:<\/b> Every 6 weeks dosing in Melanoma<br><b>Mechanism:<\/b> PD-1 Ab","<b>Drug:<\/b> Pembrolizumab<br><b>Date of Approval:<\/b> 2021-12-03<br><b>Indication:<\/b> Adjuvant Stage IIB and IIC Melanoma<br><b>Mechanism:<\/b> PD-1 Ab"],"textfont":{"size":15.1181102362205,"color":"rgba(231,107,243,1)"},"type":"scatter","mode":"text","hoveron":"points","name":"PD-1 Ab","legendgroup":"PD-1 Ab","showlegend":true,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null},{"x":[18473],"y":[3.5],"text":"Atezolizumab","hovertext":"<b>Drug:<\/b> Atezolizumab<br><b>Date of Approval:<\/b> 2020-07-30<br><b>Indication:<\/b> Unresectable or metastatic BRAF-mutated melanoma in combination with cobimetinib and vemurafenib<br><b>Mechanism:<\/b> PD-L1 Ab","textfont":{"size":15.1181102362205,"color":"rgba(255,98,188,1)"},"type":"scatter","mode":"text","hoveron":"points","name":"PD-L1 Ab","legendgroup":"PD-L1 Ab","showlegend":true,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null}],"layout":{"margin":{"t":41,"r":10,"b":-10,"l":10},"plot_bgcolor":"rgba(255,255,255,1)","paper_bgcolor":"rgba(255,255,255,1)","font":{"color":"rgba(0,0,0,1)","family":"","size":14.6118721461187},"xaxis":{"domain":[0,1],"automargin":true,"type":"linear","autorange":false,"range":[-2847.25,21160.25],"tickmode":"array","ticktext":["03/1965","03/1975","03/1985","03/1995","03/2005","03/2015"],"tickvals":[-1756,1896,5549,9201,12854,16506],"categoryorder":"array","categoryarray":["03/1965","03/1975","03/1985","03/1995","03/2005","03/2015"],"nticks":null,"ticks":"outside","tickcolor":"rgba(51,51,51,1)","ticklen":3.65296803652968,"tickwidth":0.66417600664176,"showticklabels":true,"tickfont":{"color":"rgba(77,77,77,1)","family":"","size":14},"tickangle":-0,"showline":false,"linecolor":null,"linewidth":0,"showgrid":false,"gridcolor":null,"gridwidth":0,"zeroline":false,"anchor":"y","title":{"text":"","font":{"color":null,"family":null,"size":0}},"hoverformat":".2f"},"yaxis":{"domain":[0,1],"automargin":true,"type":"linear","autorange":false,"range":[-1.01,101.01],"tickmode":"array","ticktext":["0","25","50","75","100"],"tickvals":[0,25,50,75,100],"categoryorder":"array","categoryarray":["0","25","50","75","100"],"nticks":null,"ticks":"","tickcolor":null,"ticklen":3.65296803652968,"tickwidth":0,"showticklabels":false,"tickfont":{"color":null,"family":null,"size":0},"tickangle":-0,"showline":false,"linecolor":null,"linewidth":0,"showgrid":false,"gridcolor":null,"gridwidth":0,"zeroline":false,"anchor":"x","title":{"text":"","font":{"color":null,"family":null,"size":0}},"hoverformat":".2f"},"shapes":[{"type":"rect","fillcolor":null,"line":{"color":null,"width":0,"linetype":[]},"yref":"paper","xref":"paper","x0":0,"x1":1,"y0":0,"y1":1}],"showlegend":true,"legend":{"bgcolor":"rgba(255,255,255,1)","bordercolor":"transparent","borderwidth":1.88976377952756,"font":{"color":"rgba(0,0,0,1)","family":"","size":15.9402241594022},"title":{"text":"Mechanism","font":{"color":"rgba(0,0,0,1)","family":"","size":18.5969281859693}},"orientation":"h","x":0,"y":-0.05},"hovermode":"closest","barmode":"relative","title":{"text":"<b>FDA Approvals in Melanoma<b>"},"titlefont":{"size":28,"color":"black","family":"Arial"},"subtitle":"testing","hoverlabel":{"font":{"size":16}}},"config":{"doubleClick":"reset","modeBarButtonsToAdd":["hoverclosest","hovercompare"],"showSendToCloud":false},"source":"A","attrs":{"139027f7788ad":{"yintercept":{},"type":"scatter"},"13902ae573c":{"yintercept":{}},"1390235e1247d":{"yintercept":{}},"139025022a62d":{"x":{},"y":{},"xend":{},"yend":{}},"1390212cbfd75":{"x":{},"y":{},"label":{},"text":{},"colour":{}}},"cur_data":"139027f7788ad","visdat":{"139027f7788ad":["function (y) ","x"],"13902ae573c":["function (y) ","x"],"1390235e1247d":["function (y) ","x"],"139025022a62d":["function (y) ","x"],"1390212cbfd75":["function (y) ","x"]},"highlight":{"on":"plotly_click","persistent":false,"dynamic":false,"selectize":false,"opacityDim":0.2,"selected":{"opacity":1},"debounce":0},"shinyEvents":["plotly_hover","plotly_click","plotly_selected","plotly_relayout","plotly_brushed","plotly_brushing","plotly_clickannotation","plotly_doubleclick","plotly_deselect","plotly_afterplot","plotly_sunburstclick"],"base_url":"https://plot.ly"},"evals":[],"jsHooks":[]}</script>
</div>
</div>
</div>
</div>
</div>
<div class="callout-note callout callout-style-simple no-icon callout-captioned">
<div class="callout-header d-flex align-content-center" data-bs-toggle="collapse" data-bs-target=".callout-2-contents" aria-controls="callout-2" aria-expanded="false" aria-label="Toggle callout">
<div class="callout-icon-container">
<i class="callout-icon no-icon"></i>
</div>
<div class="callout-caption-container flex-fill">
Figure 2. Front-line therapy in advanced melanoma.
</div>
<div class="callout-btn-toggle d-inline-block border-0 py-1 ps-1 pe-0 float-end"><i class="callout-toggle"></i></div>
</div>
<div id="callout-2" class="callout-2-contents callout-collapse collapse">
<div class="callout-body-container callout-body">
<p><img src="files/firstline_tx_melanoma.jpg" class="img-fluid"></p>
</div>
</div>
</div>
<p>Despite these treatment measures, primary and acquired resistance is common for all front-line therapeutic options. Unfortunately, outcomes with ICI and targeted therapies in the second-line setting have been disappointing (<strong>Figure 3</strong>).<span class="citation" data-cites="Atkins2023 Pires2021"><sup><a href="#ref-Atkins2023" role="doc-biblioref">12</a>,<a href="#ref-Pires2021" role="doc-biblioref">13</a></sup></span> Subsequently, the 5 year mortality rate in patients with stage IV disease is 50%.</p>
<div class="callout-note callout callout-style-simple no-icon callout-captioned">
<div class="callout-header d-flex align-content-center" data-bs-toggle="collapse" data-bs-target=".callout-3-contents" aria-controls="callout-3" aria-expanded="false" aria-label="Toggle callout">
<div class="callout-icon-container">
<i class="callout-icon no-icon"></i>
</div>
<div class="callout-caption-container flex-fill">
Figure 3. Efficacy of second-line therapy.
</div>
<div class="callout-btn-toggle d-inline-block border-0 py-1 ps-1 pe-0 float-end"><i class="callout-toggle"></i></div>
</div>
<div id="callout-3" class="callout-3-contents callout-collapse collapse">
<div class="callout-body-container callout-body">
<div class="cell">
<div class="cell-output-display">
<p><img src="til_therapy_files/figure-html/unnamed-chunk-3-1.png" class="img-fluid" width="672"></p>
</div>
</div>
</div>
</div>
</div>
<p>Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) has shown clinical utility in melanoma since the 1990s.<span class="citation" data-cites="rosenberg1994"><sup><a href="#ref-rosenberg1994" role="doc-biblioref">14</a></sup></span> In this process, tumor-resident T cells from a patient’s tumor are extracted and expanded ex-vivo. The patient is administered preparative lymphodepleting chemotherapy, often with cyclophosphamide and fludarabine, before the T-cells are infused back into the patient with interleukin-2 to further enhance in vivo expansion of cells and boost the antitumor response. While results have varied, multiple phase I and II trials have shown response rates around 50%.<span class="citation" data-cites="vandenberg2020 dudley2008 rosenberg2011 besser2010 ellebaek2012 andersen2016 Dudley2002 Pilon-Thomas2012"><sup><a href="#ref-vandenberg2020" role="doc-biblioref">15</a>–<a href="#ref-Pilon-Thomas2012" role="doc-biblioref">22</a></sup></span> Several of these studies are summarized in <strong>Figure 4</strong>. A recent study of LN-144 TIL therapy in patients who failed anti-PD-1 immunotherapy reported an objective response rate of 36%, highlighting potential utility of TIL therapy for patients who have had disease progression on first-line options.<span class="citation" data-cites="Sarnaik2021"><sup><a href="#ref-Sarnaik2021" role="doc-biblioref">23</a></sup></span></p>
<div class="callout-note callout callout-style-simple no-icon callout-captioned">
<div class="callout-header d-flex align-content-center" data-bs-toggle="collapse" data-bs-target=".callout-4-contents" aria-controls="callout-4" aria-expanded="false" aria-label="Toggle callout">
<div class="callout-icon-container">
<i class="callout-icon no-icon"></i>
</div>
<div class="callout-caption-container flex-fill">
Figure 4. Summary of previous TIL studies in advanced melanoma.
</div>
<div class="callout-btn-toggle d-inline-block border-0 py-1 ps-1 pe-0 float-end"><i class="callout-toggle"></i></div>
</div>
<div id="callout-4" class="callout-4-contents callout-collapse collapse">
<div class="callout-body-container callout-body">
<p><img src="files/background_til_studies.png" class="img-fluid"></p>
</div>
</div>
</div>
</section>
<section id="study-design" class="level1">
<h1>Study Design</h1>
<p>This was a phase III, multicenter, open-label trial including patients age 18-75 with unresectable stage IIIC or IV melanoma. Patients were randomized in a 1:1 ratio to receive TIL or anti-cytotoxic T-lymphocyte antigen 4 therapy (ipilimumab) (<strong>Figure 5</strong>). Patients assigned to the TIL group underwent a metastasectomy for retrieval and expansion of TILs, then received nonmyeloablative, lymphodepleting chemotherapy with cyclophosphamide and fludarabine. Single intravenous adoptive transfer of TILs was followed by high-dose interleukin-2 every 8 hours, for a maximum of 15 doses. Patients in the ipilimumab group received 3 mg per kilogram of body weight every 3 weeks, for up to 4 doses. The primary end point was progression-free survival, defined as the time from randomization to first disease progression or death. Secondary endpoints included progression-free survival (PFS), objective response, complete response, overall survival, health-related quality of life, and safety.</p>
<div class="callout-note callout callout-style-simple no-icon callout-captioned">
<div class="callout-header d-flex align-content-center" data-bs-toggle="collapse" data-bs-target=".callout-5-contents" aria-controls="callout-5" aria-expanded="false" aria-label="Toggle callout">
<div class="callout-icon-container">
<i class="callout-icon no-icon"></i>
</div>
<div class="callout-caption-container flex-fill">
Figure 5. Study design.
</div>
<div class="callout-btn-toggle d-inline-block border-0 py-1 ps-1 pe-0 float-end"><i class="callout-toggle"></i></div>
</div>
<div id="callout-5" class="callout-5-contents callout-collapse collapse">
<div class="callout-body-container callout-body">
<p><img src="files/study_design.png" class="img-fluid"></p>
</div>
</div>
</div>
</section>
<section id="main-findings" class="level1">
<h1>Main Findings</h1>
<p>168 patients (86% with disease refractory to anti–programmed death 1 treatment) were assigned to receive TILs (84 patients) or ipilimumab (84 patients). Median PFS in the TIL group was 7.2 months, significantly longer than 3.1 months in the ipilimumab group. Objective response rates were 49% in TIL group and 21% (95% CI, 13 to 32) of patients in ipilimumab group. 20% of patients in the TIL group achieved complete response, compared to 7% in the ipilimumab group. At the time of the data cutoff, the overall median follow-up was 33.0 months. Median overall survival was 25.8 months in the TIL group and 18.9 months in the ipilimumab group. In regards to safety, treatment related adverse events occurred in all patients in the TIL group and in 96% of those in the ipilimumab group. All patients in the TIL group experienced grade 3 adverse events, due to chemotherapy-related myelosuppression, while 57% of patients in the ipilimumab group experienced grade 3 or higher adverse events. Overall, patients in the TIL group had higher mean health-related quality of life scores than those in the ipilimumab group, though scores varied for different symptoms.</p>
</section>
<section id="discussion-points" class="level1">
<h1>Discussion Points</h1>
<p>Improving outcomes for patients with ICI-refractory disease is a critical need. The treatment landscape is evolving and clinicians currently have a few options to choose from when patients progress on first-line monotherapy anti-PD-1. Commercially-available options include monotherapy ipilimumab, dual ICB with ipilimumab/nivolumab or ipilimumab/relatlimab and combination targeted therapies for patients with actionable BRAF V600 mutations. When provided with a clinical vignette of ICI-refractory wild-type melanoma, the vast majority of the diverse group of COIG attendees at the January 9th journal club (<strong>Figure 6</strong>) that treat melanoma (90%; 9/10) responded that they would have selected combination ipilimumab/nivolumab (<strong>Figure 7</strong>). Given the patient’s ECOG status of 2, one respondent would have recommended combination CTLA-4/LAG-3 in this case. None of the practioners would have recommended monotherapy ipilimumab.</p>
<div class="callout-note callout callout-style-simple no-icon callout-captioned">
<div class="callout-header d-flex align-content-center" data-bs-toggle="collapse" data-bs-target=".callout-6-contents" aria-controls="callout-6" aria-expanded="false" aria-label="Toggle callout">
<div class="callout-icon-container">
<i class="callout-icon no-icon"></i>
</div>
<div class="callout-caption-container flex-fill">
Figure 6. Journal club attendees
</div>
<div class="callout-btn-toggle d-inline-block border-0 py-1 ps-1 pe-0 float-end"><i class="callout-toggle"></i></div>
</div>
<div id="callout-6" class="callout-6-contents callout-collapse collapse">
<div class="callout-body-container callout-body">
<div class="cell">

</div>
<div class="cell">

</div>
<div class="cell">
<div class="cell-output-display">
<p><img src="til_therapy_files/figure-html/attendees graph-1.png" class="img-fluid" width="960"></p>
</div>
</div>
</div>
</div>
</div>
<div class="callout-note callout callout-style-simple no-icon callout-captioned">
<div class="callout-header d-flex align-content-center" data-bs-toggle="collapse" data-bs-target=".callout-7-contents" aria-controls="callout-7" aria-expanded="false" aria-label="Toggle callout">
<div class="callout-icon-container">
<i class="callout-icon no-icon"></i>
</div>
<div class="callout-caption-container flex-fill">
Figure 7. Management strategies of ICI-refractory melanoma
</div>
<div class="callout-btn-toggle d-inline-block border-0 py-1 ps-1 pe-0 float-end"><i class="callout-toggle"></i></div>
</div>
<div id="callout-7" class="callout-7-contents callout-collapse collapse">
<div class="callout-body-container callout-body">
<div class="cell">
<div class="cell-output-display">
<p><img src="til_therapy_files/figure-html/case one-1.png" class="img-fluid" width="960"></p>
</div>
</div>
</div>
</div>
</div>
<p>Attendees recognized that while dual ICB and combination oncogene-targeted therapies can produce responses in the second-line and beyond, meaningful clinical benefit is limited to a fraction of patients. Therefore, different strategies in the refractory setting are needed. For many years, TIL therapy has produced intriguing results in small, non-comparative investigations. Given the lack of commercial approval, TIL therapy has not been widely adopted. However, the majority of melanoma clinicians at the January 9<sup>th</sup> COIG JC (62%; 5/8) have recommended TIL therapy previously as part of their practice (<strong>Figure 8</strong>) and were affiliates at institutions with a cell therapy group capable of delivery TIL therapy (<strong>Figure 9</strong>, 71%; 5/7).</p>
<div class="callout-note callout callout-style-simple no-icon callout-captioned">
<div class="callout-header d-flex align-content-center" data-bs-toggle="collapse" data-bs-target=".callout-8-contents" aria-controls="callout-8" aria-expanded="false" aria-label="Toggle callout">
<div class="callout-icon-container">
<i class="callout-icon no-icon"></i>
</div>
<div class="callout-caption-container flex-fill">
Figure 8. Experience with TIL therapy
</div>
<div class="callout-btn-toggle d-inline-block border-0 py-1 ps-1 pe-0 float-end"><i class="callout-toggle"></i></div>
</div>
<div id="callout-8" class="callout-8-contents callout-collapse collapse">
<div class="callout-body-container callout-body">
<div class="cell">
<div class="cell-output-display">
<p><img src="til_therapy_files/figure-html/unnamed-chunk-4-1.png" class="img-fluid" width="672"></p>
</div>
</div>
</div>
</div>
</div>
<div class="callout-note callout callout-style-simple no-icon callout-captioned">
<div class="callout-header d-flex align-content-center" data-bs-toggle="collapse" data-bs-target=".callout-9-contents" aria-controls="callout-9" aria-expanded="false" aria-label="Toggle callout">
<div class="callout-icon-container">
<i class="callout-icon no-icon"></i>
</div>
<div class="callout-caption-container flex-fill">
Figure 9. Cell therapy capabilities
</div>
<div class="callout-btn-toggle d-inline-block border-0 py-1 ps-1 pe-0 float-end"><i class="callout-toggle"></i></div>
</div>
<div id="callout-9" class="callout-9-contents callout-collapse collapse">
<div class="callout-body-container callout-body">
<div class="cell">
<div class="cell-output-display">
<p><img src="til_therapy_files/figure-html/unnamed-chunk-5-1.png" class="img-fluid" width="672"></p>
</div>
</div>
</div>
</div>
</div>
<p>Thus, the results from Rohaan et al were of a considerable interest. TIL therapy was associated with a clinically meaningful 50% reduction in the hazard for progression or death compared with monotherapy ipilimumab. and an impressive response rate of 49%.</p>
<p>Next, we discussed the risk versus benefit of several therapeutic options for ICI-refractory disease. As depicted in <strong>Figure 7</strong>, TIL studies have reported high rates of grade 3 or higher treatment-related adverse events (TRAEs), however they also have greater response rates than CTLA-4 directed therapy, alone or in combination with PD-1 or LAG-3 inhibitors. Almost all patients in the TIL studies experienced the expected adverse effects of lymphodepleting chemotherapy; the clinicians in the group who are familiar with TIL therapy in clinical practice emphasized that while patients are expected to get quite sick, the toxicity window is short, and patients without significant comorbidities will likely recover without permanent toxicity. IL-2 and radiation can add further toxicity, and may need to be held if a patient is tolerating treatment poorly. It is possible that patients who experienced high-grade adverse events with another therapy such as combination nivolumab/ipilimumab would not enroll in a study like this where TRAEs are expected and can be significant.</p>
<div class="callout-note callout callout-style-simple no-icon callout-captioned">
<div class="callout-header d-flex align-content-center" data-bs-toggle="collapse" data-bs-target=".callout-10-contents" aria-controls="callout-10" aria-expanded="false" aria-label="Toggle callout">
<div class="callout-icon-container">
<i class="callout-icon no-icon"></i>
</div>
<div class="callout-caption-container flex-fill">
Figure 10. Risk benefit of therapeutic strategies for PD-1 refractory disease.
</div>
<div class="callout-btn-toggle d-inline-block border-0 py-1 ps-1 pe-0 float-end"><i class="callout-toggle"></i></div>
</div>
<div id="callout-10" class="callout-10-contents callout-collapse collapse">
<div class="callout-body-container callout-body">
<div class="cell">
<div class="cell-output-display">
<div class="plotly html-widget html-fill-item-overflow-hidden html-fill-item" id="htmlwidget-bbcbd7092d558f555e41" style="width:100%;height:541px;"></div>
<script type="application/json" data-for="htmlwidget-bbcbd7092d558f555e41">{"x":{"data":[{"x":[18],"y":[57],"text":"<b>Therapy:<\/b> Ipilimumab<br><b>Study:<\/b> Netherlands Cancer Inst Study<br><b>Number of Subjects:<\/b> 84<br><b>Rate ≥3 TRAEs:<\/b> 57%<br><b>Object Response Rate:<\/b> 18%<br><b>Mechanism:<\/b> CTLA-4<br><b>Reference:<\/b> Sarnaik et al JCO 2021","type":"scatter","mode":"markers","marker":{"autocolorscale":false,"color":"rgba(248,118,109,1)","opacity":1,"size":37.7952755905512,"symbol":"square","line":{"width":1.88976377952756,"color":"rgba(248,118,109,1)"}},"hoveron":"points","name":"(CTLA-4,Netherlands Cancer Inst Study)","legendgroup":"(CTLA-4,Netherlands Cancer Inst Study)","showlegend":true,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null},{"x":[13],"y":[33],"text":"<b>Therapy:<\/b> Ipilimumab<br><b>Study:<\/b> Pires da Silva Retrospective<br><b>Number of Subjects:<\/b> 162<br><b>Rate ≥3 TRAEs:<\/b> 33%<br><b>Object Response Rate:<\/b> 13%<br><b>Mechanism:<\/b> CTLA-4<br><b>Reference:<\/b> Pires da Silva et al Lancet Oncology 2021","type":"scatter","mode":"markers","marker":{"autocolorscale":false,"color":"rgba(248,118,109,1)","opacity":1,"size":37.7952755905512,"symbol":"cross-thin-open","line":{"width":1.88976377952756,"color":"rgba(248,118,109,1)"}},"hoveron":"points","name":"(CTLA-4,Pires da Silva Retrospective)","legendgroup":"(CTLA-4,Pires da Silva Retrospective)","showlegend":true,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null},{"x":[31],"y":[31],"text":"<b>Therapy:<\/b> Ipilimumab/Anti-PD-1<br><b>Study:<\/b> Pires da Silva Retrospective<br><b>Number of Subjects:<\/b> 193<br><b>Rate ≥3 TRAEs:<\/b> 31%<br><b>Object Response Rate:<\/b> 31%<br><b>Mechanism:<\/b> CTLA-4/Anti-PD-1<br><b>Reference:<\/b> Pires da Silva et al Lancet Oncology 2021","type":"scatter","mode":"markers","marker":{"autocolorscale":false,"color":"rgba(124,174,0,1)","opacity":1,"size":37.7952755905512,"symbol":"cross-thin-open","line":{"width":1.88976377952756,"color":"rgba(124,174,0,1)"}},"hoveron":"points","name":"(CTLA-4/Anti-PD-1,Pires da Silva Retrospective)","legendgroup":"(CTLA-4/Anti-PD-1,Pires da Silva Retrospective)","showlegend":true,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null},{"x":[16],"y":[9],"text":"<b>Therapy:<\/b> Nivo/Rela<br><b>Study:<\/b> NCT01968109<br><b>Number of Subjects:<\/b> 43<br><b>Rate ≥3 TRAEs:<\/b> 9%<br><b>Object Response Rate:<\/b> 16%<br><b>Mechanism:<\/b> CTLA-4/LAG-3<br><b>Reference:<\/b> Ascierto et al JCO/ASCO 2017","type":"scatter","mode":"markers","marker":{"autocolorscale":false,"color":"rgba(0,191,196,1)","opacity":1,"size":37.7952755905512,"symbol":"triangle-up","line":{"width":1.88976377952756,"color":"rgba(0,191,196,1)"}},"hoveron":"points","name":"(CTLA-4/LAG-3,NCT01968109)","legendgroup":"(CTLA-4/LAG-3,NCT01968109)","showlegend":true,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null},{"x":[36],"y":[97],"text":"<b>Therapy:<\/b> Lifileucel<br><b>Study:<\/b>  NCT02360579<br><b>Number of Subjects:<\/b> 66<br><b>Rate ≥3 TRAEs:<\/b> 97%<br><b>Object Response Rate:<\/b> 36%<br><b>Mechanism:<\/b> TIL<br><b>Reference:<\/b> Sarnaik et al JCO 2021","type":"scatter","mode":"markers","marker":{"autocolorscale":false,"color":"rgba(199,124,255,1)","opacity":1,"size":37.7952755905512,"symbol":"circle","line":{"width":1.88976377952756,"color":"rgba(199,124,255,1)"}},"hoveron":"points","name":"(TIL, NCT02360579)","legendgroup":"(TIL, NCT02360579)","showlegend":true,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null},{"x":[41],"y":[100],"text":"<b>Therapy:<\/b> TIL-European Study<br><b>Study:<\/b> Netherlands Cancer Inst Study<br><b>Number of Subjects:<\/b> 84<br><b>Rate ≥3 TRAEs:<\/b> 100%<br><b>Object Response Rate:<\/b> 41%<br><b>Mechanism:<\/b> TIL<br><b>Reference:<\/b> Rohaan et al NEJM 2022","type":"scatter","mode":"markers","marker":{"autocolorscale":false,"color":"rgba(199,124,255,1)","opacity":1,"size":37.7952755905512,"symbol":"square","line":{"width":1.88976377952756,"color":"rgba(199,124,255,1)"}},"hoveron":"points","name":"(TIL,Netherlands Cancer Inst Study)","legendgroup":"(TIL,Netherlands Cancer Inst Study)","showlegend":true,"xaxis":"x","yaxis":"y","hoverinfo":"text","frame":null}],"layout":{"margin":{"t":20,"r":10,"b":0,"l":10},"paper_bgcolor":"rgba(255,255,255,1)","font":{"color":"Black","family":"","size":14},"xaxis":{"domain":[0,1],"automargin":true,"type":"linear","autorange":false,"range":[-2.25,47.25],"tickmode":"array","ticktext":["0","10","20","30","40"],"tickvals":[0,10,20,30,40],"categoryorder":"array","categoryarray":["0","10","20","30","40"],"nticks":null,"ticks":"outside","tickcolor":"rgba(51,51,51,1)","ticklen":3.65296803652968,"tickwidth":0.66417600664176,"showticklabels":true,"tickfont":{"color":"rgba(77,77,77,1)","family":"","size":16},"tickangle":-0,"showline":true,"linecolor":"rgba(0,0,0,1)","linewidth":0.66417600664176,"showgrid":true,"gridcolor":"rgba(255,255,255,1)","gridwidth":0.66417600664176,"zeroline":false,"anchor":"y","title":"<b>Objective Response Rate (%)<\/b>","hoverformat":".2f"},"yaxis":{"domain":[0,1],"automargin":true,"type":"linear","autorange":false,"range":[-5.1,107.1],"tickmode":"array","ticktext":["0","10","20","30","40","50","60","70","80","90","100"],"tickvals":[0,10,20,30,40,50,60,70,80,90,100],"categoryorder":"array","categoryarray":["0","10","20","30","40","50","60","70","80","90","100"],"nticks":null,"ticks":"outside","tickcolor":"rgba(51,51,51,1)","ticklen":3.65296803652968,"tickwidth":0.66417600664176,"showticklabels":true,"tickfont":{"color":"rgba(77,77,77,1)","family":"","size":16},"tickangle":-0,"showline":true,"linecolor":"rgba(0,0,0,1)","linewidth":0.66417600664176,"showgrid":true,"gridcolor":"rgba(255,255,255,1)","gridwidth":0.66417600664176,"zeroline":false,"anchor":"x","title":"<b>Grade ≥3 TRAEs (%)<\/b>","hoverformat":".2f"},"shapes":[{"type":"rect","fillcolor":null,"line":{"color":null,"width":0,"linetype":[]},"yref":"paper","xref":"paper","x0":0,"x1":1,"y0":0,"y1":1}],"showlegend":true,"legend":{"bgcolor":"rgba(255,255,255,1)","bordercolor":"transparent","borderwidth":1.88976377952756,"font":{"color":"rgba(0,0,0,1)","family":"","size":14},"orientation":"h","x":0,"y":-0.45},"hovermode":"closest","barmode":"relative","hoverlabel":{"font":{"size":20}}},"config":{"doubleClick":"reset","modeBarButtonsToAdd":["hoverclosest","hovercompare"],"showSendToCloud":false},"source":"A","attrs":{"139027bdf5df6":{"x":{},"y":{},"colour":{},"shape":{},"text":{},"type":"scatter"}},"cur_data":"139027bdf5df6","visdat":{"139027bdf5df6":["function (y) ","x"]},"highlight":{"on":"plotly_click","persistent":false,"dynamic":false,"selectize":false,"opacityDim":0.2,"selected":{"opacity":1},"debounce":0},"shinyEvents":["plotly_hover","plotly_click","plotly_selected","plotly_relayout","plotly_brushed","plotly_brushing","plotly_clickannotation","plotly_doubleclick","plotly_deselect","plotly_afterplot","plotly_sunburstclick"],"base_url":"https://plot.ly"},"evals":[],"jsHooks":[]}</script>
</div>
</div>
</div>
</div>
</div>
<p>After our discussion, we re-surveyed respondents about how they would manage a case of ICI-refractory melanoma in a 71 year-old patient with ICI-refractory melanoma. Only 1/9 clinicians responded that they would recommend TIL therapy (<strong>Figure 8</strong>). Notably, the question states the patient has an ECOG of 2, which may make clinicians reluctant to give a regimen that is difficult to tolerate to someone with such limited performance status.</p>
<div class="callout-note callout callout-style-simple no-icon callout-captioned">
<div class="callout-header d-flex align-content-center" data-bs-toggle="collapse" data-bs-target=".callout-11-contents" aria-controls="callout-11" aria-expanded="false" aria-label="Toggle callout">
<div class="callout-icon-container">
<i class="callout-icon no-icon"></i>
</div>
<div class="callout-caption-container flex-fill">
Figure 11. Practice changing nature of the study
</div>
<div class="callout-btn-toggle d-inline-block border-0 py-1 ps-1 pe-0 float-end"><i class="callout-toggle"></i></div>
</div>
<div id="callout-11" class="callout-11-contents callout-collapse collapse">
<div class="callout-body-container callout-body">
<div class="cell">
<div class="cell-output-display">
<p><img src="til_therapy_files/figure-html/unnamed-chunk-6-1.png" class="img-fluid" width="672"></p>
</div>
</div>
</div>
</div>
</div>
<div class="callout-note callout callout-style-simple no-icon callout-captioned">
<div class="callout-header d-flex align-content-center" data-bs-toggle="collapse" data-bs-target=".callout-12-contents" aria-controls="callout-12" aria-expanded="false" aria-label="Toggle callout">
<div class="callout-icon-container">
<i class="callout-icon no-icon"></i>
</div>
<div class="callout-caption-container flex-fill">
Figure 12. Case one revisted
</div>
<div class="callout-btn-toggle d-inline-block border-0 py-1 ps-1 pe-0 float-end"><i class="callout-toggle"></i></div>
</div>
<div id="callout-12" class="callout-12-contents callout-collapse collapse">
<div class="callout-body-container callout-body">
<div class="cell">
<div class="cell-output-display">
<p><img src="til_therapy_files/figure-html/unnamed-chunk-7-1.png" class="img-fluid" width="672"></p>
</div>
</div>
</div>
</div>
</div>
<p>Finally, respondents were asked whether TIL therapy would become their preferred regimen for ICI-refractory melanoma if it were FDA-approved. The results were close, with 4/9 respondents answering ‘yes’ and 5/9 responding ‘no’ (<strong>Figure 9</strong>). One responded brought up the point that the decision must be individualized. It is important to consider whether a patient has a large enough metastases for extraction of resident T cells from the tumor; thus TIL therapy may be better suited for a patient with bulky lymphadenopathy rather than immeasurable disseminated disease. One must also consider how long the harvesting process takes.</p>
<p>Notably, 19 patients in this study received TIL as first-line therapy. As ICIs move into the adjuvant and neoadjuvant setting, subsequent studies will likely explore TIL as a first-line option for metastatic disease in the appropriate patients.</p>
<div class="callout-note callout callout-style-simple no-icon callout-captioned">
<div class="callout-header d-flex align-content-center" data-bs-toggle="collapse" data-bs-target=".callout-13-contents" aria-controls="callout-13" aria-expanded="false" aria-label="Toggle callout">
<div class="callout-icon-container">
<i class="callout-icon no-icon"></i>
</div>
<div class="callout-caption-container flex-fill">
Figure 9. Implementation of TIL therapy
</div>
<div class="callout-btn-toggle d-inline-block border-0 py-1 ps-1 pe-0 float-end"><i class="callout-toggle"></i></div>
</div>
<div id="callout-13" class="callout-13-contents callout-collapse collapse">
<div class="callout-body-container callout-body">
<div class="cell">
<div class="cell-output-display">
<p><img src="til_therapy_files/figure-html/unnamed-chunk-8-1.png" class="img-fluid" width="672"></p>
</div>
</div>
</div>
</div>
</div>
<section id="materials-and-methods" class="level2">
<h2 class="anchored" data-anchor-id="materials-and-methods">Materials and Methods</h2>
<p>This <code>Perspectives on the Science</code> piece was published using <a href="https://quarto.org">Quarto</a><sup>®</sup>. The survey was conducted using REDCap<sup>®</sup>.<span class="citation" data-cites="Harris2009"><sup><a href="#ref-Harris2009" role="doc-biblioref">24</a></sup></span> The figures depicting the survey data were created using R (version 4.0.0) and the tidyverse suite of packages<span class="citation" data-cites="tidyverse"><sup><a href="#ref-tidyverse" role="doc-biblioref">25</a></sup></span>, including ggplot2<span class="citation" data-cites="ggplot2"><sup><a href="#ref-ggplot2" role="doc-biblioref">26</a></sup></span> .</p>
<div style="background-color:#F5F5F5; margin-left: 0px; padding: 0px; padding-left: 0px; font-size: 12px">
<p>This site represents our opinions only. See our full <a href="https://www.themillerlab.io/privacy/">Disclaimer</a> and <a href="https://www.themillerlab.io/terms/">Terms of Use Agreement</a></p>
</div>
</section>
</section>
<section id="author-affiliations" class="level1">
<h1>Author Affiliations</h1>
<ol type="1">
<li>Brigham and Women’s Hospital, Boston MA</li>
<li>Mass General Cancer Center and Harvard Medical School, Boston MA</li>
<li>GW Cancer Center, George Washington University School of Medicine &amp; Health Sciences, Washington DC</li>
<li>Pennsylvania Hospital and University of Pennsylvania, Philadelphia PA</li>
<li>Visiting Fellow in the Dermatology Branch at the National Institute of Arthritis and Musculoskeletal and Skin Diseases</li>
</ol>
<section id="disclosures" class="level2">
<h2 class="anchored" data-anchor-id="disclosures">Disclosures</h2>
<p>DMM reports grants and personal fees from Regeneron, grants from Kartos Therapeutics, grants from NeoImmuneTech, personal fees from Checkpoint Therapeutics, personal fees from Pfizer, personal fees from Merck Sharpe &amp; Dome, personal fees from EMD Serono, grants from Project DataSphere, personal fees from Sanofi Genzyme, personal fees from Castle Biosciences, personal fees from Avstera, outside the submitted work. SZS reports no competing interests.</p>



</section>
</section>

<div id="quarto-appendix" class="default"><section class="quarto-appendix-contents" role="doc-bibliography"><h2 class="anchored quarto-appendix-heading">References</h2><div id="refs" class="references csl-bib-body" data-line-spacing="2" role="doc-bibliography">
<div id="ref-Rohaan2022" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">1. </div><div class="csl-right-inline">Rohaan, M. W. <em>et al.</em> <a href="https://doi.org/10.1056/nejmoa2210233">Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma</a>. <em>New England Journal of Medicine</em> <strong>387</strong>, 2113–2125 (2022).</div>
</div>
<div id="ref-Hamid2019" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">2. </div><div class="csl-right-inline">Hamid, O. <em>et al.</em> <a href="https://doi.org/10.1093/annonc/mdz011">Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001</a>. <em>Annals of Oncology</em> <strong>30</strong>, 582–588 (2019).</div>
</div>
<div id="ref-Robert2015" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">3. </div><div class="csl-right-inline">Robert, C. <em>et al.</em> <a href="https://doi.org/10.1056/nejmoa1503093">Pembrolizumab versus Ipilimumab in Advanced Melanoma</a>. <em>New England Journal of Medicine</em> <strong>372</strong>, 2521–2532 (2015).</div>
</div>
<div id="ref-Robert2019" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">4. </div><div class="csl-right-inline">Robert, C. <em>et al.</em> <a href="https://doi.org/10.1016/s1470-2045(19)30388-2">Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study</a>. <em>The Lancet Oncology</em> <strong>20</strong>, 1239–1251 (2019).</div>
</div>
<div id="ref-Schachter2017" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">5. </div><div class="csl-right-inline">Schachter, J. <em>et al.</em> <a href="https://doi.org/10.1016/s0140-6736(17)31601-x">Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)</a>. <em>The Lancet</em> <strong>390</strong>, 1853–1862 (2017).</div>
</div>
<div id="ref-Petrella2017" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">6. </div><div class="csl-right-inline">Petrella, T. M. <em>et al.</em> <a href="https://doi.org/10.1016/j.ejca.2017.08.032">Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma</a>. <em>European Journal of Cancer</em> <strong>86</strong>, 115–124 (2017).</div>
</div>
<div id="ref-wolchok2017" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">7. </div><div class="csl-right-inline">Wolchok, J. D. <em>et al.</em> <a href="https://doi.org/10.1056/nejmoa1709684">Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma</a>. <em>New England Journal of Medicine</em> <strong>377</strong>, 1345–1356 (2017).</div>
</div>
<div id="ref-tawbi2022" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">8. </div><div class="csl-right-inline">Tawbi, H. A. <em>et al.</em> <a href="https://doi.org/10.1056/nejmoa2109970">Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma</a>. <em>New England Journal of Medicine</em> <strong>386</strong>, 24–34 (2022).</div>
</div>
<div id="ref-long2022" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">9. </div><div class="csl-right-inline">Long, G. V. <em>et al.</em> <a href="https://doi.org/10.1200/jco.2022.40.36_suppl.360385">Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)</a>. <em>Journal of Clinical Oncology</em> <strong>40</strong>, 360385–360385 (2022).</div>
</div>
<div id="ref-robert2019a" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">10. </div><div class="csl-right-inline">Robert, C. <em>et al.</em> <a href="https://doi.org/10.1056/nejmoa1904059">Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma</a>. <em>New England Journal of Medicine</em> <strong>381</strong>, 626–636 (2019).</div>
</div>
<div id="ref-dummer2018" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">11. </div><div class="csl-right-inline">Dummer, R. <em>et al.</em> <a href="https://doi.org/10.1016/s1470-2045(18)30142-6">Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial</a>. <em>The Lancet Oncology</em> <strong>19</strong>, 603–615 (2018).</div>
</div>
<div id="ref-Atkins2023" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">12. </div><div class="csl-right-inline">Atkins, M. B. <em>et al.</em> <a href="https://doi.org/10.1200/jco.22.01763">Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <span><em>BRAF</em></span>-Mutant Melanoma: The DREAMseq Trial<span></span>ECOG-ACRIN EA6134</a>. <em>Journal of Clinical Oncology</em> <strong>41</strong>, 186–197 (2023).</div>
</div>
<div id="ref-Pires2021" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">13. </div><div class="csl-right-inline">Silva, I. Pires da <em>et al.</em> <a href="https://doi.org/10.1016/s1470-2045(21)00097-8">Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study</a>. <em>The Lancet Oncology</em> <strong>22</strong>, 836–847 (2021).</div>
</div>
<div id="ref-rosenberg1994" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">14. </div><div class="csl-right-inline">Rosenberg, S. A. <em>et al.</em> <a href="https://doi.org/10.1093/jnci/86.15.1159">Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2</a>. <em>JNCI Journal of the National Cancer Institute</em> <strong>86</strong>, 1159–1166 (1994).</div>
</div>
<div id="ref-vandenberg2020" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">15. </div><div class="csl-right-inline">Berg, J. H. van den <em>et al.</em> <a href="https://doi.org/10.1136/jitc-2020-000848">Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up</a>. <em>Journal for ImmunoTherapy of Cancer</em> <strong>8</strong>, e000848 (2020).</div>
</div>
<div id="ref-dudley2008" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">16. </div><div class="csl-right-inline">Dudley, M. E. <em>et al.</em> <a href="https://doi.org/10.1200/jco.2008.16.5449">Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens</a>. <em>Journal of Clinical Oncology</em> <strong>26</strong>, 5233–5239 (2008).</div>
</div>
<div id="ref-rosenberg2011" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">17. </div><div class="csl-right-inline">Rosenberg, S. A. <em>et al.</em> <a href="https://doi.org/10.1158/1078-0432.ccr-11-0116">Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy</a>. <em>Clinical Cancer Research</em> <strong>17</strong>, 4550–4557 (2011).</div>
</div>
<div id="ref-besser2010" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">18. </div><div class="csl-right-inline">Besser, M. J. <em>et al.</em> <a href="https://doi.org/10.1158/1078-0432.ccr-10-0041">Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients</a>. <em>Clinical Cancer Research</em> <strong>16</strong>, 2646–2655 (2010).</div>
</div>
<div id="ref-ellebaek2012" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">19. </div><div class="csl-right-inline">Ellebaek, E. <em>et al.</em> <a href="https://doi.org/10.1186/1479-5876-10-169">Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients</a>. <em>Journal of Translational Medicine</em> <strong>10</strong>, (2012).</div>
</div>
<div id="ref-andersen2016" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">20. </div><div class="csl-right-inline">Andersen, R. <em>et al.</em> <a href="https://doi.org/10.1158/1078-0432.ccr-15-1879">Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen</a>. <em>Clinical Cancer Research</em> <strong>22</strong>, 3734–3745 (2016).</div>
</div>
<div id="ref-Dudley2002" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">21. </div><div class="csl-right-inline">Dudley, M. <em>et al.</em> A phase i study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific t lymphocytes in patients with metastatic melanoma. <em>Journal of Immunotherapy</em> (2022) doi:<a href="https://doi.org/10.1097/01.CJI.0000016820.36510.89">10.1097/01.CJI.0000016820.36510.89</a>.</div>
</div>
<div id="ref-Pilon-Thomas2012" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">22. </div><div class="csl-right-inline">Pilon-Thomas, S. <em>et al.</em> <a href="https://doi.org/10.1097/cji.0b013e31826e8f5f">Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma</a>. <em>Journal of Immunotherapy</em> <strong>35</strong>, 615–620 (2012).</div>
</div>
<div id="ref-Sarnaik2021" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">23. </div><div class="csl-right-inline">Sarnaik, A. A. <em>et al.</em> <a href="https://doi.org/10.1200/jco.21.00612">Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma</a>. <em>Journal of Clinical Oncology</em> <strong>39</strong>, 2656–2666 (2021).</div>
</div>
<div id="ref-Harris2009" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">24. </div><div class="csl-right-inline">Harris, P. A. <em>et al.</em> <a href="https://doi.org/10.1016/j.jbi.2008.08.010">Research electronic data capture (REDCap)<span></span>A metadata-driven methodology and workflow process for providing translational research informatics support</a>. <em>Journal of Biomedical Informatics</em> <strong>42</strong>, 377–381 (2009).</div>
</div>
<div id="ref-tidyverse" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">25. </div><div class="csl-right-inline">Wickham, H. <em>et al.</em> <a href="https://doi.org/10.21105/joss.01686">Welcome to the <span></span>tidyverse<span></span></a>. <strong>4</strong>, 1686 (2019).</div>
</div>
<div id="ref-ggplot2" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">26. </div><div class="csl-right-inline">Wickham, H. <em><a href="https://ggplot2.tidyverse.org">ggplot2: Elegant graphics for data analysis</a></em>. (Springer-Verlag New York, 2016).</div>
</div>
</div></section></div></main> <!-- /main -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const disableStylesheet = (stylesheets) => {
    for (let i=0; i < stylesheets.length; i++) {
      const stylesheet = stylesheets[i];
      stylesheet.rel = 'prefetch';
    }
  }
  const enableStylesheet = (stylesheets) => {
    for (let i=0; i < stylesheets.length; i++) {
      const stylesheet = stylesheets[i];
      stylesheet.rel = 'stylesheet';
    }
  }
  const manageTransitions = (selector, allowTransitions) => {
    const els = window.document.querySelectorAll(selector);
    for (let i=0; i < els.length; i++) {
      const el = els[i];
      if (allowTransitions) {
        el.classList.remove('notransition');
      } else {
        el.classList.add('notransition');
      }
    }
  }
  const toggleColorMode = (alternate) => {
    // Switch the stylesheets
    const alternateStylesheets = window.document.querySelectorAll('link.quarto-color-scheme.quarto-color-alternate');
    manageTransitions('#quarto-margin-sidebar .nav-link', false);
    if (alternate) {
      enableStylesheet(alternateStylesheets);
      for (const sheetNode of alternateStylesheets) {
        if (sheetNode.id === "quarto-bootstrap") {
          toggleBodyColorMode(sheetNode);
        }
      }
    } else {
      disableStylesheet(alternateStylesheets);
      toggleBodyColorPrimary();
    }
    manageTransitions('#quarto-margin-sidebar .nav-link', true);
    // Switch the toggles
    const toggles = window.document.querySelectorAll('.quarto-color-scheme-toggle');
    for (let i=0; i < toggles.length; i++) {
      const toggle = toggles[i];
      if (toggle) {
        if (alternate) {
          toggle.classList.add("alternate");     
        } else {
          toggle.classList.remove("alternate");
        }
      }
    }
    // Hack to workaround the fact that safari doesn't
    // properly recolor the scrollbar when toggling (#1455)
    if (navigator.userAgent.indexOf('Safari') > 0 && navigator.userAgent.indexOf('Chrome') == -1) {
      manageTransitions("body", false);
      window.scrollTo(0, 1);
      setTimeout(() => {
        window.scrollTo(0, 0);
        manageTransitions("body", true);
      }, 40);  
    }
  }
  const isFileUrl = () => { 
    return window.location.protocol === 'file:';
  }
  const hasAlternateSentinel = () => {  
    let styleSentinel = getColorSchemeSentinel();
    if (styleSentinel !== null) {
      return styleSentinel === "alternate";
    } else {
      return false;
    }
  }
  const setStyleSentinel = (alternate) => {
    const value = alternate ? "alternate" : "default";
    if (!isFileUrl()) {
      window.localStorage.setItem("quarto-color-scheme", value);
    } else {
      localAlternateSentinel = value;
    }
  }
  const getColorSchemeSentinel = () => {
    if (!isFileUrl()) {
      const storageValue = window.localStorage.getItem("quarto-color-scheme");
      return storageValue != null ? storageValue : localAlternateSentinel;
    } else {
      return localAlternateSentinel;
    }
  }
  let localAlternateSentinel = 'default';
  // Dark / light mode switch
  window.quartoToggleColorScheme = () => {
    // Read the current dark / light value 
    let toAlternate = !hasAlternateSentinel();
    toggleColorMode(toAlternate);
    setStyleSentinel(toAlternate);
  };
  // Ensure there is a toggle, if there isn't float one in the top right
  if (window.document.querySelector('.quarto-color-scheme-toggle') === null) {
    const a = window.document.createElement('a');
    a.classList.add('top-right');
    a.classList.add('quarto-color-scheme-toggle');
    a.href = "";
    a.onclick = function() { try { window.quartoToggleColorScheme(); } catch {} return false; };
    const i = window.document.createElement("i");
    i.classList.add('bi');
    a.appendChild(i);
    window.document.body.appendChild(a);
  }
  // Switch to dark mode if need be
  if (hasAlternateSentinel()) {
    toggleColorMode(true);
  } else {
    toggleColorMode(false);
  }
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    target: function(trigger) {
      return trigger.previousElementSibling;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn) {
    const config = {
      allowHTML: true,
      content: contentFn,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start'
    };
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
</div> <!-- /content -->



</body></html>